Prognostic value of p16 in locally advanced prostate cancer: A study based on Radiation Therapy Oncology Group protocol 9202

Journal of Clinical Oncology

Volumn 25, Issue 21, 2007, Pages 3082-3089

  Chakravarti, Arnab ^a   DeSilvio, Michelle ^a   Zhang, Min ^a   Grignon, David ^a   Rosenthal, Seth ^a   Asbell, Sucha O ^a   Hanks, Gerald ^a   Sandler, Howard M ^a   Khor, Li Yan ^a   Pollack, Alan ^a   Shipley, William ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIANDROGEN; FLUTAMIDE; GOSERELIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P16; RETINOBLASTOMA PROTEIN; SURVIVIN;

ADULT; ADVANCED CANCER; AGED; ANDROGEN RELEASE; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE;

AGED; ANDROGEN ANTAGONISTS; BIOPSY, NEEDLE; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; REFERENCE VALUES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34547653605     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.4152     Document Type: Article

References (19)

1. Harbour JW, Dean DC: The pRB/E2F pathway: Expanding roles and emerging paradigms. Genes Dev 14:2393-2409, 2000
2. Nevins JR: The Rb/E2F pathway and cancer. Hum Mol Genet 10:699-703, 2001
3. Pan H, Yin C, Dyson NJ, et al: Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol Cell 2:283-292, 1998
4. Chakravarti A, Heydon K, Wu C-L, et al: Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from the Radiation Therapy Oncology Group protocol 8610. J Clin Oncol 21:3328-3334, 2003
5. Pilepich MV, Krall JM, Al-Sarraf M, et al: Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 45:616-623, 1995
6. Hanks GE, Pajak TF, Porter AC, et al: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 9202. J Clin Oncol 21:3972-3978, 2003
7. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
8. Kalbfleish JD, Prentice RL: The Statistical Analysis of Failure Times Data. New York, NY, John Wiley, 1980
9. Takeuchi H, Ozawa S, Ando N, et al: Altered P16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 3:2229-2236, 1997
10. Namazie A, Alavi S, Olopade O, et al: Cyclin D1 amplification and p16 (MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 112:472-481, 2002
11. Gessner C, Liebers U, Kuhn H, et al: BAX and p16INK4a are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J 19:134-140, 2002
12. Jarrard DF, Bova GS, Ewing CM, et al: Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19:90-96, 1997
13. Li J, Wang E, Rinaldo F, et al: Upregulation of VEGF-C by androgen depletion: The involvement of IGF-1R-FOXO pathway. Oncogene 24:5510-5520, 2005
14. Niculescu T, Weerth S, Soane L, et al: Effects of membrane attack complex of complement on apoptosis in experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 1010:530-533, 2003
15. Boddy JL, Fox SB, Han C, et al: The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 11:7658-7663, 2005
16. Lara PN Jr, Twardowski P, Quinn DI: Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer 3:165-173, 2004
17. Gustavsson H, Welen K, Damber JE: Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 62:364-373, 2005
18. Harada H, Nakagawa K, Iwata S, et al: Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 59: 3783-3789, 1999
19. Miki K, Shimizu E, Yano S, et al: Demethylation by 5-aza-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines. Oncol Res 12:335-342, 2001